Goldman Sachs Maintains Neutral on Calumet, Raises Price Target to $45

Benzinga · 2d ago
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $40 to $45.